Display Settings:

Format

Send to:

Choose Destination
Hum Psychopharmacol. 2003 Jul;18(5):389-93.

Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder.

Author information

  • 1Regional Hospital of Bolzano, Department of Pediatria, I-39100 Bolzano, Italy. helmut.niederhofer@uibk.ac.at

Abstract

OBJECTIVES:

Many autistic children have problems of eye contact and expressive language that limit the effectiveness of educational and behavioural interventions. Few controlled psychopharmacological trials have been conducted in autistic children to determine which agents may be effective for these associated features.

METHODS:

Twelve male children (7.3 +/- 3.3 years) with autistic disorder, diagnosed by ICD-10 criteria, completed a placebo-controlled, double-blind crossover trial of tianeptine, which lasted for 12 weeks. Subjects were included in the study if their eye contact and expressive language was inadaequate for their developmental level. Subjects had not tolerated or responded to other psychopharmacological treatments (neuroleptics, methylphenidate, clonidine or desipramine).

RESULTS:

Teacher ratings on the aberrant behaviour checklist irritability, stereotypy and inappropriate speech factors were lower during treatment with tianeptine than during treatment with placebo. Clinician ratings (children's psychiatric rating scale autism, anger and speech deviance factors; children's global assessment scale; clinical global impressions efficacy) of videotaped sessions were not significantly different between tianeptine and placebo.

DISCUSSION:

Tianeptine were modestly effective in the short-term treatment of irritability in some children with autistic disorder.

Copyright 2003 John Wiley & Sons, Ltd.

PMID:
12858327
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk